Trial Profile

A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjogren's Syndrome (SS)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dazodalibep (Primary)
Indications Sjogren's syndrome
Focus Proof of concept; Therapeutic Use
Sponsors Viela Bio

Most Recent Events

15 Jun 2024 Results evaluating the effects of DAZ on the serum proteome, presented at the 25th Annual Congress of the European League Against Rheumatism
01 Jun 2024 Results published in the Nature Medicine
02 May 2024 According to an Amgen media release, a manuscript based on data from the Phase 2 Dazodalibep Sjogren's disease study has been accepted for publication in Nature Medicine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com